Results 111 to 120 of about 152,693 (210)

Central Stimulants in a Stressed Brain: Evidence Synthesis of Benefits, Burnout Risk, and Clinical Safeguards in ADHD. [PDF]

Neuropsychiatr Dis Treat
Amiri D, Briziarelli L, Shah SJ, Amiri S, Madani N, Karlsson B.   +5 more
europepmc   +1 more source

Manufacturing Supply Chains and Imports in the ADHD Drug Shortage.

JAMA Health Forum
Currie J, Malinovskaya A.
europepmc   +1 more source

Using supermarket loyalty card data to investigate seasonal variation in laxative purchases in the UK. [PDF]

PLOS Digit Health
Burgess R, Poon N, Sloan E, Goulding J, Bould H, Skatova A.   +5 more
europepmc   +1 more source

Prescribing Practices, Motivations, and Behaviors Contributing to Prescription Stimulant Misuse Among Medical Students at an Allopathic Medical School: Cross-Sectional Survey Study. [PDF]

Cureus
Short HB, Lehman E, Nelluri S, Latronica J, Bali B.   +4 more
europepmc   +1 more source

Prescription psychostimulants or atomoxetine and the risk of stimulant-related hospital admissions in adults with and without stimulant use disorder: a Swedish population-based within-individual observational study. [PDF]

Lancet Reg Health Eur
Bach P, Franck J, Hällgren J, Widing H, Gissler M, Westman J.   +5 more
europepmc   +1 more source

Stimulant Use Disorder Diagnoses in Adolescent and Young Adult Medicaid Enrollees. [PDF]

JAMA Psychiatry
Bushnell G, Keyes KM, Zhu Y, Cerdá M, Gerhard T, Hasin D, Iizuka A, Lloyd K, Samples H, Olfson M.   +9 more
europepmc   +1 more source

From Control to Care: Reframing Medication Access Policies Through Public Health Ethics. [PDF]

J Law Med Ethics
Jaffe K, Evans EA.
europepmc   +1 more source

Polydrug use with opioid involvement: Results from a national sample of U.S. civilians aged 12 years or older. [PDF]

PLoS One
Ding K, Bista S, Welter T, Wheeler KK, Smith GA, Yang J.   +5 more
europepmc   +1 more source

Trends of incident stimulant use disorder diagnoses before and after the COVID-19 pandemic in British Columbia (2013-2024): a population-based study. [PDF]

Front Psychiatry
Desai R, Hu K, Zhao B, Au S, Chen X, Flynn M, Irvine M, Sbihi H, Kinniburgh B, Sedgemore KO, Marchand K, Bartlett S, Janjua N, Crabtree A, Palis H.   +14 more
europepmc   +1 more source

Economic Evaluation of Extended-Release Amphetamine (Dyanavel XR) Among Individuals with Attention-Deficit/Hyperactivity Disorder From a United States Societal Perspective. [PDF]

Clinicoecon Outcomes Res
Chopra I, Horng J, Krause MS, Sellinger EP, Potenziano J.   +4 more
europepmc   +1 more source